Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BSX
HoldUnloved QualityBoston Scientific Corporation · Healthcare · United States · $67.9B · Avg Vol: $922M/d
COMPANY DESCRIPTION
Boston Scientific Corporation is a global developer, manufacturer, and marketer of interventional medical devices across specialties including cardiology, peripheral interventions, urology, and gastrointestinal health. The company maintains a strong competitive position through its robust R&D pipeline, extensive patent portfolio, and deep-rooted relationships with healthcare systems, which drive high switching costs for its advanced solutions. As a significant player in the medical technology sector, it consistently introduces innovative, life-changing devices.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.7B | 14.2B | 16.7B | 20.1B | 16.5% | 21.0B | 21.4B | 22.3B | 5.5% |
| EPS | 0.45 | 1.08 | 1.26 | 1.96 | 63.3% | 2.47 | 2.12 | 2.20 | 5.9% |
| Shares | 1.4B | 1.5B | 1.5B | 1.5B | +3.5% | 1.4B | — | — | — |
| Debt | 9.3B | 9.5B | 10.7B | 11.4B | 7.2% | 12.6B | — | — | — |
| Equity | 17.6B | 19.3B | 21.8B | 24.2B | 11.3% | — | — | — | — |
| Op CF | 1.5B | 2.5B | 3.4B | 4.5B | 43.8% | 4.5B | — | — | — |
| Inv CF | -2.0B | -2.6B | -5.7B | -2.6B | — | — | — | — | — |
| Fin CF | -548.0M | 5.0M | 1.8B | -395.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BSX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BSX | Boston Scientific Corporation(you) | $67.9B | 48 | Hold |
| SHL.DE | Siemens Healthineers AG | $51.3B | 62 | Hold |
| EW | Edwards Lifesciences Corporation | $52.0B | 64 | Hold |
| SYK | Stryker Corporation | $126.8B | 57 | Hold |
| GEHC | GE HealthCare Technologies Inc. | $32.4B | 63 | Hold |
| 300760.SZ | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | $29.6B | 63 | Hold |
| ABT | Abbott Laboratories | $194.6B | 61 | Hold |
| PEN | Penumbra, Inc. | $12.7B | 51 | Hold |
| PODD | Insulet Corporation | $10.1B | 48 | Hold |
| GKOS | Glaukos Corporation | $10.6B | 46 | Hold |
Peer medians: ROE 2.9% · P/E 24.4x · Gross margin 52.6%